Article | June 7, 2023

Second Line Therapy: The Past, Present, And Future Of Treating Hematological Cancers

Source: Biorasi

By Robert S. Negrin, MD, Professor of Medicine and former Chief of the Division of Blood and Marrow Transplantation at Stanford University, Biorasi Scientific Advisory Board member

GettyImages-667825028 cancer

Hematological cancers make up nearly 10 percent of new cancer cases in the United States, encompassing lymphoma, leukemia, and myeloma, with 13 subtypes. Each year, over 600,000 deaths are attributed to blood cancer. The primary treatment for the most common lymphoma type, diffuse large B cell lymphoma, is the CHOP chemotherapy and antibody regimen, comprising cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (oncovin), and prednisone. However, advancements in cell therapy offer alternative options for patients if the initial treatment proves ineffective.

“Unfortunately, about 40 percent of patients relapse after frontline treatment, and the cancer returns,” noted Dr. Robert Negrin. “The standard response in this situation had been to recommend a bone marrow transplant. Today, when compared to transplant options, for some patients, CAR T-cell therapy has been shown to be a superior treatment and it has been moved up to the second line of treatment after chemotherapy and CHOP for those patients who relapse within 12 months of initial therapy.”

What was once science fiction has moved up to second line therapy, which gives greater access to patients and allows for a greater impact. In this article, Dr. Negrin navigates the trajectory of CAR T-Cell Therapy from early HIV therapy to second line treatment for diffuse large B cell lymphoma.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader